JP2014502156A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014502156A5 JP2014502156A5 JP2013541211A JP2013541211A JP2014502156A5 JP 2014502156 A5 JP2014502156 A5 JP 2014502156A5 JP 2013541211 A JP2013541211 A JP 2013541211A JP 2013541211 A JP2013541211 A JP 2013541211A JP 2014502156 A5 JP2014502156 A5 JP 2014502156A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- peptide according
- isolated
- vector
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000023 polynucleotide Polymers 0.000 claims 7
- 239000002157 polynucleotide Substances 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 235000001014 amino acid Nutrition 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 102000038129 antigens Human genes 0.000 claims 4
- 108091007172 antigens Proteins 0.000 claims 4
- 230000001575 pathological Effects 0.000 claims 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 235000009697 arginine Nutrition 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 102000019679 Cell-Penetrating Peptides Human genes 0.000 claims 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims 1
- 208000006572 Human Influenza Diseases 0.000 claims 1
- 206010022000 Influenza Diseases 0.000 claims 1
- 150000001484 arginines Chemical class 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 150000001945 cysteines Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 101710031453 groL2 Proteins 0.000 claims 1
- 239000000568 immunological adjuvant Substances 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 230000035943 smell Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229960005486 vaccines Drugs 0.000 claims 1
- 230000003612 virological Effects 0.000 claims 1
Claims (20)
- 下記の構造：
X1-X2-X3-X4-X5 (式Ｉ)
(式中、X1及びX3は、独立して、１、２又は３つのアルギニンの直鎖配列を意味し；X2 及びX 4 はHCV、CMV、HPV若しくはインフルエンザの同じ抗原又は該抗原の変異型配列であって、該抗原と比較して１〜10の置換、付加若しくは欠失を含み、その天然型配列と少なくとも50％の配列同一性を有する変異型配列からの８〜15アミノ酸の直鎖配列を意味し；X4 はX 2とは異なり；X5は、随意に存在してもよいアルギニンである)
を含んでなる単離された細胞透過性ペプチド。 - １以上のシステインを含んでなる、請求項１に記載の単離ペプチド。
- X2中のＮ-及び/又はＣ-末端アミノ酸が親水性又は極性アミノ酸である、請求項１又は２に記載の単離ペプチド。
- X4中のＮ-末端アミノ酸が親水性又は極性アミノ酸である、請求項１〜３のいずれか１項に記載の単離ペプチド。
- X1 及び/又はX 3 が２又は３アミノ酸からなる、請求項１〜４のいずれか１項に記載の単離ペプチド。
- X1 がRRからなる、請求項５に記載の単離ペプチド。
- X3 がRRからなる、請求項５又は６に記載の単離ペプチド。
- X2 及び/又はX 4 が12アミノ酸未満の直鎖配列である、請求項１〜７のいずれか１項に記載の単離ペプチド。
- 各ペプチド単量体が請求項１〜８のいずれか１項に記載のペプチドである２つのペプチド単量体を含んでなる二量体ペプチド。
- 請求項１〜８のいずれか１項に記載のペプチドを２以上含んでなるペプチドの組合せ。
- 請求項１〜８のいずれか１項に記載のペプチドをコードする単離された核酸又はポリヌクレオチド。
- 請求項１１に記載の核酸若しくはポリヌクレオチドを含んでなるベクター又は該ベクターを含んでなる宿主細胞。
- 少なくとも、請求項１〜８のいずれか１項に記載のペプチド、請求項９に記載の二量体ペプチド、請求項１０に記載のペプチドの組合せ、請求項１１に記載の核酸若しくはポリヌクレオチド又は請求項１２に記載のベクターを、医薬的に許容され得る希釈剤若しくはビヒクル及び随意に免疫学的アジュバントと組み合わせて含んでなる免疫原性組成物。
- ワクチン組成物の形態である請求項１３に記載の免疫原性組成物。
- 対象者において抗原に対する免疫応答を誘導する方法での使用のための、請求項１〜８のいずれか１項に記載のペプチド、請求項９に記載の二量体ペプチド、請求項１０に記載のペプチドの組合せ、請求項１１に記載の核酸若しくはポリヌクレオチド又は請求項１２に記載のベクター又は請求項１３若しくは１４に記載の組成物。
- 対象者においてウイルスの病理学的効果を減少させ及び/又は遅延させる方法での使用のための、請求項１〜８のいずれか１項に記載のペプチド、請求項９に記載の二量体ペプチド、請求項１０に記載のペプチドの組合せ、請求項１１に記載の核酸若しくはポリヌクレオチド又は請求項１２に記載のベクター又は請求項１３若しくは１４に記載の組成物。
- 医薬に使用するための、請求項１〜８のいずれか１項に記載のペプチド。
- 対象者においてウイルスの病理学的効果を治療する方法での使用のための請求項１〜８のいずれか１項に記載のペプチド。
- 請求項１〜８のいずれか１項に記載のペプチド、請求項９に記載の二量体ペプチド、請求項１０に記載のペプチドの組合せ、請求項１１に記載の核酸若しくはポリヌクレオチド又は請求項１２に記載のベクターの、対象者において抗原に対する免疫応答を誘導する組成物の製造における使用。
- 請求項１〜８のいずれか１項に記載のペプチド、請求項９に記載の二量体ペプチド、請求項１０に記載のペプチドの組合せ、請求項１１に記載の核酸若しくはポリヌクレオチド又は請求項１２に記載のベクターの、対象者においてウイルスの病理学的効果を減少させ及び/又は遅延させるための組成物の製造における使用。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10193479 | 2010-12-02 | ||
| EP10193479.2 | 2010-12-02 | ||
| US201161475965P | 2011-04-15 | 2011-04-15 | |
| US61/475,965 | 2011-04-15 | ||
| PCT/DK2011/050460 WO2012072088A1 (en) | 2010-12-02 | 2011-12-02 | Peptide scaffold design |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014502156A JP2014502156A (ja) | 2014-01-30 |
| JP2014502156A5 true JP2014502156A5 (ja) | 2014-12-18 |
| JP6069212B2 JP6069212B2 (ja) | 2017-02-01 |
Family
ID=44022075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013541211A Active JP6069212B2 (ja) | 2010-12-02 | 2011-12-02 | ペプチド骨格設計 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9550811B2 (ja) |
| EP (1) | EP2646459B1 (ja) |
| JP (1) | JP6069212B2 (ja) |
| CN (1) | CN103282375B (ja) |
| AU (1) | AU2011335551B2 (ja) |
| CA (1) | CA2819416C (ja) |
| EA (1) | EA025152B1 (ja) |
| NZ (1) | NZ611176A (ja) |
| WO (1) | WO2012072088A1 (ja) |
| ZA (1) | ZA201304017B (ja) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6294076B2 (ja) | 2011-01-06 | 2018-03-14 | ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ | 多量体ペプチド |
| CA2875624A1 (en) | 2012-06-06 | 2013-12-12 | Bionor Immuno As | Hiv vaccine |
| NZ702146A (en) | 2012-06-06 | 2016-11-25 | Bionor Immuno As | Peptides derived from viral proteins for use as immunogens and dosage reactants |
| WO2015007337A1 (en) | 2013-07-19 | 2015-01-22 | Bionor Immuno As | Method for the vaccination against hiv |
| CN104436157A (zh) | 2013-09-23 | 2015-03-25 | 恩金生物有限公司 | 流感疫苗和治疗 |
| US10080792B2 (en) | 2013-09-23 | 2018-09-25 | Engen Bio, Inc. | Influenza vaccine and therapy |
| JP2016034944A (ja) * | 2014-08-04 | 2016-03-17 | 日東電工株式会社 | Ｃｔｌのアポトーシスを抑制するまたｃｔｌの誘導抑制を阻害するワクチン医薬組成物 |
| CA2957501C (en) * | 2014-08-17 | 2020-08-11 | Cellivery Therapeutics, Inc. | Advanced macromolecule transduction domain (amtd) sequences for improvement of cell-permeability, polynucleotides encoding the same, method to identify the unique features of amtds comprising the same, method to develop the amtd sequences comprising the same |
| US20160060314A1 (en) | 2014-08-27 | 2016-03-03 | Daewoong Jo | Development of a Protein-Based Biotherapeutic Agent That Penetrates Cell-Membrane and Induces Anti-Tumor Effect in Solid Tumors - Improved Cell-Permeable Suppressor of Cytokine Signaling (iCP-SOCS3) Proteins, Polynucleotides Encoding the Same, and Anti-Tumor Compositions Comprising the Same |
| CN107847544B (zh) * | 2015-07-20 | 2021-10-15 | 小利兰·斯坦福大学董事会 | 用多聚体结合试剂检测细胞表型和定量 |
| US20170029798A1 (en) | 2015-07-27 | 2017-02-02 | Cellivery Therapeutics, Inc. | Development of Improved Cell-Permeable (iCP) Parkin Recombinant Protein as a Protein-Based Anti-Neurodegenerative Agent for the Treatment of Parkinson's Disease-Associated Phenotypes by Utilizing BBB-Penetrating Protein Delivery System MITT, Enabled by Advanced Macromolecule Transduction Domain (aMTD) |
| WO2017026776A1 (en) | 2015-08-10 | 2017-02-16 | Cellivery Therapeutics, Inc. | Improved cell-permeable reprogramming factor (icp-rf) recombinant protein and use thereof |
| EP3334756B1 (en) | 2015-08-10 | 2020-06-17 | Cellivery Therapeutics, Inc. | Improved cell-permeable cre (icp-cre) recombinant protein and use thereof |
| WO2017030323A1 (en) | 2015-08-18 | 2017-02-23 | Cellivery Therapeutics, Inc. | Cell-permeable (cp)-δsocs3 recombinant protein and uses thereof |
| RU2628690C2 (ru) * | 2015-11-06 | 2017-08-21 | Общество С Ограниченной Ответственностью 'Фарминтерпрайсез' | Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний |
| WO2018017443A1 (en) * | 2016-07-18 | 2018-01-25 | President And Fellows Of Harvard College | Immunogenic compositions and methods relating thereto |
| GB201812980D0 (en) * | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| EP3912989A4 (en) * | 2018-11-02 | 2022-05-18 | Institute of Basic Medical Sciences Chinese Academy of Medical Sciences | PENETRATING PEPTIDE BASED ON THE M2 PROTEIN OF THE INFLUENZA VIRUS |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4606918A (en) | 1983-08-22 | 1986-08-19 | Syntex (U.S.A.) Inc. | Polyoxypropylene-polyoxyethylene block polymer based adjuvants |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| CA1292686C (en) | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
| CA1294215C (en) | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| DE4209215A1 (de) | 1991-07-04 | 1993-01-07 | Boehringer Mannheim Gmbh | Hcv peptidantigene und verfahren zur bestimmung von hcv |
| MA22842A1 (fr) | 1992-03-27 | 1993-10-01 | Smithkline Beecham Biolog | Procede de preparation de compositions de vaccin. |
| CA2136429C (en) | 1992-05-23 | 2001-12-11 | Jean Petre | Combined vaccines comprising hepatitis b surface antigen and other antigens |
| DE69327599T2 (de) | 1992-06-25 | 2000-08-10 | Smithkline Beecham Biolog | Adjuvantien enthaltende Impfstoffzusammensetzung |
| ATE204762T1 (de) | 1993-03-23 | 2001-09-15 | Smithkline Beecham Biolog | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
| ATE415173T1 (de) | 1993-09-14 | 2008-12-15 | Pharmexa Inc | Pan dr-bindeproteinen zur erhöhung der immunantwort |
| DE69432475T2 (de) | 1993-11-04 | 2004-03-04 | Innogenetics N.V. | Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US5709995A (en) | 1994-03-17 | 1998-01-20 | The Scripps Research Institute | Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses |
| DE69517521T2 (de) | 1994-04-08 | 2001-03-08 | Us Gov Health & Human Serv | Peptid aus dem inneren des hepatitis-c-virus brauchbar für die stimulation cytotoxischer t-lymphocyten und die diagnose des hcv-kontaktes |
| GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| CN1330377C (zh) * | 1996-03-10 | 2007-08-08 | 明治乳业株式会社 | 用于治疗***反应疾病的基于肽的免疫治疗剂 |
| ATE296313T1 (de) | 1996-03-21 | 2005-06-15 | Epimmune Inc | Hla-a2.1 bindende peptide und deren verwendung |
| EP0935662B1 (en) | 1996-05-24 | 2005-11-30 | Chiron Corporation | Multiple epitope fusion protein |
| US6566330B1 (en) | 1996-10-22 | 2003-05-20 | Medical University Of South Carolina Foundation Research Development | Positively charged non-natural amino acids, methods of making and using thereof in peptides |
| GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| NO311807B1 (no) * | 1999-03-04 | 2002-01-28 | Bionor Immuno As | HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV |
| EP1200109A4 (en) | 1999-07-19 | 2005-06-15 | Epimmune Inc | USE OF PEPTIDE NUCLEIC ACID COMPOUNDS TO TRIGGER CELLULAR IMMUNE RESPONSES TO HEPATITIS C |
| US6258932B1 (en) | 1999-08-09 | 2001-07-10 | Tripep Ab | Peptides that block viral infectivity and methods of use thereof |
| US20020076415A1 (en) | 1999-12-14 | 2002-06-20 | Jing-Hsiung Ou | Hepatitis C virus gene products |
| GB0005703D0 (en) | 2000-03-09 | 2000-05-03 | Alpharma As | Compounds |
| WO2002020035A1 (en) | 2000-09-01 | 2002-03-14 | Epimmune Inc. | Hla binding peptides and their uses |
| EP1195381A1 (de) | 2000-09-28 | 2002-04-10 | Immusystems GmbH | CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope |
| GB0026094D0 (en) | 2000-10-25 | 2000-12-13 | Imp College Innovations Ltd | Methods |
| FR2824326B1 (fr) | 2001-05-04 | 2004-03-19 | Commissariat Energie Atomique | Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications |
| AUPR593101A0 (en) | 2001-06-26 | 2001-07-19 | Council Of The Queensland Institute Of Medical Research, The | Cytomegalovirus t cell epitopes |
| FR2839722A1 (fr) | 2002-05-17 | 2003-11-21 | Bio Merieux | Nouvelles compositions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c |
| US7702465B2 (en) | 2002-06-10 | 2010-04-20 | Algonomics N.V. | Method, computing routine, device for predicting properties of MHC/peptide complexes, and data and peptides produced therefrom |
| EP1537418A2 (en) | 2002-09-13 | 2005-06-08 | Intercell AG | Method for isolating hepatitis c virus peptides |
| CN1756763B (zh) | 2003-01-15 | 2010-05-26 | 株式会社国际癌症免疫研究所 | 二聚体化肽 |
| GB0716992D0 (en) | 2007-08-31 | 2007-10-10 | Immune Targeting Systems Its L | Influenza antigen delivery vectors and constructs |
| GB0408164D0 (en) * | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
| EP1652858A1 (en) | 2004-10-28 | 2006-05-03 | Innogenetics N.V. | Peptides for inducing a CTL and/or HTL response to hepatitis C virus |
| EP1906998A4 (en) | 2005-06-01 | 2010-02-17 | Variation Biotechnologies Inc | GRAPE VACCINE FORMULATION ON PEPTIDE BASE |
| WO2008107400A1 (en) * | 2007-03-02 | 2008-09-12 | Genimmune N.V. | Hcv polyepitope construct and uses thereof |
| CA2688589A1 (en) | 2007-05-31 | 2008-12-31 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Intradermal hpv peptide vaccination |
| US8071540B2 (en) | 2007-07-13 | 2011-12-06 | University of Pittsburgh—of the Commonwealth System of Higher Education | Virus derived antimicrobial peptides |
| US20100019186A1 (en) * | 2008-07-25 | 2010-01-28 | Eaton Corporation | Engine valve assembly with valve can mountable to an engine cover |
| CN101412747B (zh) | 2008-10-21 | 2011-04-20 | 中国药科大学 | 新型穿膜肽及其用途 |
| US20110318830A1 (en) * | 2008-11-12 | 2011-12-29 | The Regents Of The University Of California | Compositions and methods for re-programming and re-differentiating cells |
| US20120121537A1 (en) | 2009-01-12 | 2012-05-17 | Chaomin Sun | Methods and Compositions for Inhibiting Hepatitis C Virus Replication |
-
2011
- 2011-12-02 CN CN201180058235.0A patent/CN103282375B/zh not_active Expired - Fee Related
- 2011-12-02 WO PCT/DK2011/050460 patent/WO2012072088A1/en active Application Filing
- 2011-12-02 AU AU2011335551A patent/AU2011335551B2/en active Active
- 2011-12-02 CA CA2819416A patent/CA2819416C/en active Active
- 2011-12-02 EP EP11844256.5A patent/EP2646459B1/en active Active
- 2011-12-02 US US13/991,108 patent/US9550811B2/en active Active
- 2011-12-02 JP JP2013541211A patent/JP6069212B2/ja active Active
- 2011-12-02 NZ NZ611176A patent/NZ611176A/en not_active IP Right Cessation
- 2011-12-02 EA EA201390806A patent/EA025152B1/ru not_active IP Right Cessation
-
2013
- 2013-05-31 ZA ZA2013/04017A patent/ZA201304017B/en unknown
-
2016
- 2016-12-21 US US15/386,963 patent/US20170112917A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014502156A5 (ja) | ||
| JP2014534202A5 (ja) | ||
| JP2015524422A5 (ja) | ||
| RU2015132962A (ru) | Иммуногенные композиции на основе вируса гриппа и их применение | |
| JP2015501840A5 (ja) | ||
| JP2014503206A5 (ja) | ||
| JP2016534034A5 (ja) | ||
| JP2014507144A5 (ja) | 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物 | |
| RU2017113571A (ru) | Рекомбинантные вакцины от fmdv и их применение | |
| BR112013032723A2 (pt) | antígenos amplamente reativos computacionalmente otimizados para influenza h1n1 | |
| JP2016506416A5 (ja) | ||
| RU2019139064A (ru) | Композиции и способы для лечения цитомегаловируса | |
| JP2018148890A5 (ja) | ||
| JP2015214545A5 (ja) | ||
| JP2013507907A5 (ja) | ||
| JP2012501959A5 (ja) | ||
| JP2009540801A5 (ja) | ||
| RU2014135703A (ru) | Оптимизированные с помощью компьютера антигены с широким спектром реактивности для вирусов гриппа h3n2, h2n2 и b | |
| JP2014507146A5 (ja) | ||
| JP2015509707A5 (ja) | ||
| JP2015529678A5 (ja) | ||
| JP2014509838A5 (ja) | ||
| JP2014519817A5 (ja) | ||
| AR108781A1 (es) | Aumento de la inmunogenicidad del péptido l2 de virus de papiloma humano (hpv) | |
| JP2015506705A5 (ja) |